Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H33N3O5S |
Molecular Weight | 511.633 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(N(CSC1(C)C)C(=O)[C@@H](O)[C@H](CC2=CC=CC=C2)NC(=O)C3=C(C)C(O)=CC=C3)C(=O)NCC=C
InChI
InChIKey=LXRNKYYBEZMYNM-ACIOBRDBSA-N
InChI=1S/C27H33N3O5S/c1-5-14-28-25(34)23-27(3,4)36-16-30(23)26(35)22(32)20(15-18-10-7-6-8-11-18)29-24(33)19-12-9-13-21(31)17(19)2/h5-13,20,22-23,31-32H,1,14-16H2,2-4H3,(H,28,34)(H,29,33)/t20-,22-,23+/m0/s1
Molecular Formula | C27H33N3O5S |
Molecular Weight | 511.633 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:38:07 UTC 2023
by
admin
on
Fri Dec 15 15:38:07 UTC 2023
|
Record UNII |
USI577N9VE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000042363
Created by
admin on Fri Dec 15 15:38:07 UTC 2023 , Edited by admin on Fri Dec 15 15:38:07 UTC 2023
|
PRIMARY | |||
|
USI577N9VE
Created by
admin on Fri Dec 15 15:38:07 UTC 2023 , Edited by admin on Fri Dec 15 15:38:07 UTC 2023
|
PRIMARY | |||
|
478410-84-3
Created by
admin on Fri Dec 15 15:38:07 UTC 2023 , Edited by admin on Fri Dec 15 15:38:07 UTC 2023
|
PRIMARY | |||
|
DTXSID90460038
Created by
admin on Fri Dec 15 15:38:07 UTC 2023 , Edited by admin on Fri Dec 15 15:38:07 UTC 2023
|
PRIMARY | |||
|
11249242
Created by
admin on Fri Dec 15 15:38:07 UTC 2023 , Edited by admin on Fri Dec 15 15:38:07 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiretroviral; Mechanism of Action: Peptide hydrolase inhibitor; Highest Development Phase: Discontinued for HIV infections; Most Recent Events: 11 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral Infections antimicrobial activity section, 06 Jan 2005 Phase-II clinical trials in HIV infections treatment in USA (unspecified route)
|
||
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |
Hammond reports AG-001859 is a potent, tight binding inhibitor of both wild-type HIV protease and an I84V/L90M mutant HIV protease, exhibiting a Ki of <0.1 nM against both enzymes. In cell-based assays, AG-001859 demonstrated potent antiviral activity against several strains of wild-type HIV, including laboratory adapted and primary isolates, with EC50 values ranging from 14 to 60 nM. The median IC50 (amount of drug to suppress replication) for AG-001859 against the 80% of the viruses was 75 nM, but it was higher for the other drugs: 278 Nm for nelfinavir, 119 nM for Kaletra, 92 nM for saquinavir, 130 nM for amprenavir, and 323 nM for indinavir.
|